Cascadian Therapeutics announces closing of $46.0 million concurrent stock offerings
Cascadian Therapeutics announced it has closed a public offering of 40,250,000 shares of its common stock at a price to the public of $0.80 per share for gross proceeds of $32.2 million. In addition, Cascadian Therapeutics closed offering of 17,250 shares of its Series D Convertible Preferred Stock. June 28, 2016